EGFR and non-small cell lung carcinoma: Moreover, a network meta-analysis of RCTs, comparing the OS of advanced NSCLC with wild-type or unknown EGFR status treated according to second-line treatment, found no association between nivolumab vs. pembrolizumab (HR = 1.03, 0.77 to 1.40), nivolumab vs. atezolizumab (HR = 1.06, 0.82 to 1.37) or pembrolizumab vs. atezolizumab (HR = 1.03, 0.77 to 1.36) [10].